Express Scripts Value-Based Program To Leverage Generic Advair

Pharmacy benefit manager Express Scripts plans to shake up the asthma/pulmonary and multiple sclerosis categories in 2018 with new contracting programs.

CrackedEggs_1200x675

Pharmacy benefit manager Express Scripts Holding Co. will roll out a value-based purchasing program in 2018 in the pulmonary drug category that will leverage the competition offered by an expected generic version of GlaxoSmithKline PLC's Advair Diskus (fluticasone/salmeterol) to lower costs.

"Our clients are clamoring from some reprieve from Advair in asthma, pulmonary conditions. So that will be the cornerstone of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

Trump Administration Closer to Unprecedented Drug Price Transparency Requirements

 
• By 

New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.

Orphan Drug Relief Still In Budget Bill But Uncertainty Remains

 
• By 

The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.

More from Market Access

Orphan Drug Relief Still In Budget Bill But Uncertainty Remains

 
• By 

The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.

No ‘Doomsday’ For US Pharma Despite Political Uncertainties, EU Industry Chief Says

 

While challenges in the US present an “incredible opportunity” for Europe, there is no “doomsday” happening there, Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says.

Oz Says Big PBMs Have ‘Window’ to Quit Rebate System on Their Own

 
• By 

CMS Administrator Mehmet Oz said PBMs may deserve "one last chance" to fix the rebate system before federal regulations and legislation are enacted.